Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program

Main Article Content

Lawrence Eichenfeld
UC San Diego

Jonathan Silverberg
George Washington University School of Medicine

Robert Bissonnette
Innovaderm Research Inc., Montreal, QC, Canada

Anna Tallman
Dermavant Sciences, Inc., Morrisville, NC, USA

David Rubenstein
Dermavant Sciences, Inc., Morrisville, NC, USA

Stephen Piscitelli
Dermavant Sciences, Inc., Morrisville, NC, USA

John Jett
Dermavant Sciences, Inc., Morrisville, NC, USA

Keywords

tapinarof, atopic dermatitis, ADORING trial

Abstract

N/A

References

1. Weidinger S & Novak N. Lancet. 2016;387:1109–1122;

2. Bieber T. N Engl J Med. 2008;358:1483–1494;

3. Carroll CL, et al. Pediatr Dermatol. 2005;22:192–199;

4. Lewis-Jones S. Int J Clin Pract. 2006;60:984–992;

5. National Eczema Association. https://nationaleczema.org/research/eczema-facts/.
Accessed May 2021;

6. Bissonnette R, et al. J Am Acad Dermatol. 2021;84:1059–1067;

7. Dermavant DOF [DMVT-505 Th2 Polarization; Apr 2015];

8. Dermavant DOF [DMVT-505 AD Mouse Model; Oct 2016];

9. Smith SH, et al. J Invest Dermatol. 2017;137:2110–2119;

10. Kim BE, et al. Allergy Asthma Immunol Res. 2018;10:207–215;

11. Peppers J, et al. J Am Acad Dermatol. 2019;80:89–98;

12. Paller A, et al. J Am Acad Dermatol. 2021;84:632–638

Article Sidebar

Poster PDF
Published
Nov 5, 2021
DOI https://doi.org/10.25251/skin.5.supp.62

Article Details

How to Cite
Eichenfeld, L., Silverberg, J., Bissonnette, R., Tallman, A., Rubenstein, D., Piscitelli, S., & Jett, J. (2021). Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program . SKIN The Journal of Cutaneous Medicine, 5(6), s62. https://doi.org/10.25251/skin.5.supp.62
Issue
Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>